We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

MaxCyte

Ideally placed to sustain growth

Update | 17 July 2019

Mereo BioPharma

Accelerated approval path for NAVI

Lighthouse | 16 July 2019

Scancell

Ground prepared for an important period

Lighthouse | 01 July 2019

Hutchison China MediTech

Secondary ADS offering trims CK Hutchison stake

Lighthouse | 28 June 2019

BerGenBio

Private placement to support randomised Phase II trials

Update | 19 June 2019

Hutchison China MediTech

Surufatinib on track for potential 2020 China approval

Update | 18 June 2019

Hutchison China MediTech

Impressive data means SANET-ep trial stopped early

Lighthouse | 14 June 2019

Scancell

Vulpes investment brings £3.88m in new funds

Lighthouse | 13 June 2019

BerGenBio

ASCO: more supportive data for bemcentinib

Update | 05 June 2019

Mereo BioPharma

Encouraging interim BPS-804 data in OI

Update | 31 May 2019
1 2 3 4 5 6 7 8 9 10 11 12 13 14
136 results found.